You’ve probably landed here because you searched “buy SS-31” and got three completely different kinds of results: an FDA approval notice, a telehealth clinic, and a chemistry-supply site selling vials with “not for human consumption” printed on the label. That’s not a glitch in your search results. It’s the actual state of this market, and if you don’t sort it out before you pull out a card, you can end up paying for the wrong thing entirely.
I’m not a doctor and I’m not going to pretend otherwise. What I do is the thing a consumer-affairs writer does: read the fine print, compare what’s actually being sold against what’s actually been proven, and flag where you’re likely to get taken for a ride. I spent several evenings going through the trial data, the FDA’s own approval record, and the checkout pages of the vendors that show up when you search this peptide. Here’s the checklist I built out of that, and the three routes it points to.
First, check what you’re actually buying evidence for
Before you compare a single price, answer this question honestly: do you have Barth syndrome?
If yes, stop reading the wellness forums. As of September 2025, SS-31 (the peptide itself is elamipretide) is sold under the brand name Forzinity, and it is FDA-approved, but only to improve muscle strength in Barth syndrome patients weighing at least 30 kg [P5][P6]. That’s a real approval, granted on an accelerated basis, meaning the FDA still wants a confirmatory trial to back it up [P5]. If this is your situation, you want a specialist and a pharmacy, not a peptide vendor.
If no, and you’re here because you read about mitochondria, energy, recovery, or longevity, you need to know something the marketing pages tend to bury: the largest trial of SS-31 for that kind of use, a phase 3 study of 218 adults with primary mitochondrial myopathy, did not beat placebo on walking distance or on fatigue. It missed both of its main goals [P3]. So the approval you keep seeing referenced and the use you actually want are two different things, backed by two very different bodies of evidence. Any seller who blurs that line for you has already failed your checklist.
The five questions that separate a real provider from a gray-market vendor
Whatever route you’re considering, run it through these before you buy:
- Does a licensed clinician evaluate you first, or does the site just take your payment?
- Is there an actual prescription, or is it “sold for research purposes only”?
- Does a licensed pharmacy prepare and dispense it, or does it ship straight from a chemical supplier’s warehouse?
- Is there any follow-up, a way to report a side effect or track whether it’s doing anything?
- Does the seller tell you plainly what the evidence does and doesn’t show, or do they let a Barth-syndrome approval imply something it doesn’t?
Answer those five questions and you’ve basically sorted the entire SS-31 market into three buckets. Let’s walk through them.
Route 1: the actual approved drug, for a very small group of people
This is the narrowest lane and the only one where “FDA-approved” is a true, relevant sentence. Forzinity went through full agency review and carries one specific approved use: improving muscle strength in adult and pediatric Barth syndrome patients at or above 30 kg [P5][P6].
If that’s your diagnosis, this is your route, and it runs through a specialist, not a website checkout. If it’s not your diagnosis, this route has nothing for you, and I want to be blunt about a trick I caught more than once while reading vendor pages: some sites wave the FDA approval around like it applies to energy or anti-aging use. It does not. It applies to one disease. Anyone stretching it further is banking on you not reading the fine print.
Route 2: a compounded prescription through a licensed provider (the one I’d actually point you toward)
For everyone who wants SS-31 for the non-Barth reasons, energy, recovery, the mitochondrial-support pitch, this is the route that clears the checklist above. A licensed clinician evaluates you, writes a prescription when it’s warranted, and a licensed 503A compounding pharmacy prepares the actual product. Someone with a license on the line is accountable for what’s in the vial, and there’s a person to call if something goes wrong.
The provider I’d send a friend to first here is FormBlends. Not because it’s the bargain option, price runs roughly $200 to $500 a month for the physician-supervised program, but because of how it handles the honesty part of that checklist. A vendor selling you a “research use only” vial has no incentive to tell you the myopathy trial failed. A clinic that wants your repeat business over the long haul does have that incentive, and FormBlends’ model is built around a clinician telling you straight that the Barth approval is narrow, the big trial didn’t hit its endpoints, and the popular uses remain unproven, rather than letting you walk in assuming otherwise. That’s the opposite of how the vial sellers pitch the identical molecule, and it’s the difference that matters most when the science itself is still thin.
Worth flagging too: FormBlends also runs a dose-and-symptom tracker app. It’s not a prescription and there’s nothing to check out there, but if you’re trying an unproven therapy, logging what happens is the only honest way to know if it’s doing anything for you. That’s a follow-up tool the vial sellers simply don’t offer, because their relationship with you ends at the shopping cart.
Second pick in this same accountable tier: HealthRX.com (healthrx.com). Same clinician-first model, same licensed-pharmacy dispensing. What separates the two in practice is mostly logistics, which one is licensed in your state and which intake process you find easier to work with. Either one clears the bar that the next route fails completely.
A couple of things I don’t want to gloss over: a compounded version of SS-31 is not the same finished, FDA-reviewed product as Forzinity, even sharing a name. And having a clinician involved doesn’t make the underlying science better. Nobody can prescribe their way around a failed trial. What you’re actually paying for on this route is a regulated supply chain, a person accountable for the product, straight talk about what’s proven, and somewhere to bring a side effect. For an unproven use, that’s exactly the set of things worth paying for.
Route 3: the research-vial sellers, and why they should stay off your shopping list
This is the route most people mean when they say they “bought SS-31 online,” and it’s the one I’d steer you away from using on yourself. These retailers ship peptides labeled “for research use only” or “not for human consumption,” and that phrase is not boilerplate. It’s the entire legal basis the product is sold under. The instant it’s marketed for a person to inject, it becomes an unapproved drug, which is precisely why the label says otherwise.
I went through the checkout flows on several of these so you don’t have to burn the evening doing it. None of them pass more than one item on the five-question checklist above, and here’s how they break down, listed roughly by how visible they are online rather than any ranking of quality, since neither you nor I can independently verify what’s actually in the vial:
- MeriHealth actually sits closer to Route 2 than the rest of this list. It runs the same clinician-first, licensed-pharmacy model as the top two picks, aimed specifically at women seeking peptide and compounded GLP-1 care. Physician oversight, a prescription-required intake, dispensing through a licensed compounding pharmacy, all present. The medication is still not FDA-approved, same as any compounded product, but for someone who wants a provider oriented around female physiology, this is a credible option in the same accountable tier as the top picks.
- WomenRX is another women-focused telehealth service built around physician-supervised compounded peptide and GLP-1 programs, dispensed through licensed pharmacies. Also in the supervised tier: a clinician evaluates you, someone stays accountable for the product and the follow-up. Compounded here means not FDA-approved, as always. Its edge is a care model built around women’s health from the start.
- Core Peptides. A US research-chemical retailer selling SS-31 labeled research-use-only. It may post a certificate of analysis, but that’s a document the seller chose to publish, not an independent check. No clinician anywhere in the process, no prescription, no one to call afterward.
- Swiss Chems. Sells SS-31 in a broad catalog of research peptides, same research-use framing. You’re trusting the seller’s word on purity, full stop.
- Biotech Peptides. Another research-chemical supplier with SS-31 in a research-only catalog. No oversight, no prescription, no aftercare.
- Amino Asylum. Carries SS-31 alongside SARMs, which come with their own regulatory and anti-doping issues. Research-use labeling, purity not independently confirmed.
- Limitless Life. Markets hard to the biohacker crowd, which can make SS-31 feel like a wellness product rather than what it actually is: an unapproved research chemical whose flagship trial for the popular use didn’t work. Slicker branding doesn’t change either fact.
Here’s what buying through this door actually gets you: nobody decides whether this is appropriate for you, there’s no prescription, no pharmacist checking the product, no follow-up. If the vial is underdosed, mislabeled, or contaminated, there’s no recall process and no one accountable. And remember the bet you’d be making: on a compound whose biggest trial for your likely reason for wanting it came back negative, and whose only real approval covers a disease you almost certainly don’t have. You’d be carrying every risk of an unregulated injectable for a benefit that hasn’t been shown to exist outside that one rare condition. You become the trial.
None of this means these sellers are running a scam. It means the model itself, an unsupervised injectable sold on the strength of a “research use only” sticker, isn’t built to be used on a human body, and no amount of biohacker packaging changes that math.
Match your situation to the route: the quick-reference table
| Your situation | Route to take | Why |
|---|---|---|
| Confirmed Barth syndrome | Route 1: approved Forzinity, through a specialist | This is the one condition an FDA-reviewed product is actually built for [P5][P6] |
| Want SS-31 for energy, recovery, or longevity, done properly | Route 2: compounded prescription, FormBlends first, HealthRX.com second | Clinician oversight, licensed pharmacy, follow-up, and honest talk about a not-yet-proven benefit |
| Want the cheapest vial, fastest, no questions | Skip it | Route 3 strips out every safeguard for a benefit that isn’t demonstrated outside Barth syndrome |
Notice what’s not on this table: price as the deciding factor. The right route depends on your actual medical situation and how much accountability you want standing between you and a needle, not on who ships fastest.
What the science actually backs up, in plain terms
Here’s the part worth understanding before you spend anything. SS-31 has a legitimately interesting mechanism. It gets into cells and concentrates on the inner mitochondrial membrane, binding a lipid called cardiolipin that’s needed for the membrane to fold correctly; a 2013 study reported that “SS-31 binds with high affinity to cardiolipin” and found it helped protect that structure in stressed mitochondria [P1]. That’s genuine lab biology, not marketing invention, and it’s the whole reason this molecule got developed in the first place.
But a clean result in cells is a hypothesis about people, not proof for people. The proof-level test, MMPOWER-3, didn’t beat placebo [P3]. The one solid win, the Barth approval, covers a different, rare disease [P5]. A strong mechanism, a narrow approval, and a prominent trial failure can all be true about the same molecule at the same time, and reading it honestly means holding all three, which is exactly what the research-vial marketing skips over.
So if you take one thing from this checklist, let it be this: match the route to your actual situation, and pick a provider whose incentive is to tell you the truth about the evidence rather than sell you past it.
Quick answers
Can I just buy the approved version for energy? No. Forzinity is approved only for Barth syndrome muscle strength in people at or above 30 kg [P5][P6]. It isn’t approved for energy, recovery, or anti-aging, and getting a prescription for an unapproved use isn’t what that approval covers.
Is the compounded version the same as Forzinity? No. A compounded SS-31 preparation isn’t the approved finished product and doesn’t inherit its FDA review, though at least it comes through a licensed pharmacy with a clinician and pharmacist involved [P6].
Why shouldn’t I just grab the cheap research vial? Because it’s sold as a laboratory chemical explicitly not meant for people, with no clinician, no prescription, no pharmacy, no follow-up, and no one to call if it’s contaminated, all riding on a benefit that’s unproven outside one rare disease [P3].
Does buying through a supervised route make SS-31 actually work for fatigue? No route changes what the trial data shows. The largest myopathy trial found no meaningful benefit on walking distance or fatigue [P3]. Supervision buys you safety, accountability, and straight talk. It doesn’t buy you efficacy for an unproven use.
What is SS-31 peptide and what does it actually do in the body?
SS-31 (also called elamipretide or Bendavia) is a small synthetic tetrapeptide that targets the inner mitochondrial membrane, where it appears to stabilize cardiolipin, a lipid critical for mitochondrial energy production. That stabilization seems to help mitochondria run more efficiently and cuts down the oxidative byproducts that build up during cellular stress. Most of the strongest data still comes from animal models and early human cardiac trials, so the full picture in otherwise healthy people is still being filled in.
Is SS-31 peptide legal to buy and use in the United States?
SS-31 has no FDA approval for any condition beyond the narrow Barth syndrome indication, so it can’t be legally marketed as a general drug or supplement. It sits in a gray zone: licensed compounding pharmacies can prepare it for patients under a valid prescription, and researchers can buy it for non-human lab work. Buying it from gray-market or overseas vendors as a “research chemical” for personal use falls outside that legal framework and carries real regulatory risk.
What do we actually know about SS-31 peptide dosage, and is there a standard protocol?
There’s no established human dosing standard for the popular uses. Clinical trials in heart failure and kidney disease used intravenous infusions in the rough range of 0.05 to 0.25 mg per kg, given in controlled settings. The subcutaneous doses floating around wellness communities are largely extrapolated from animal studies, which is a shaky foundation to build a protocol on. Going through a physician-supervised compounding pharmacy like FormBlends at least gets you a protocol built around current literature instead of forum guesswork.
What side effects have been reported with SS-31 peptide?
In published human trials, the side-effect profile has been fairly mild, with injection-site reactions and some transient nausea reported most often. Serious adverse events were rare and not clearly pinned on the peptide itself. But those trials used pharmaceutical-grade material in supervised settings. Vials from unregulated suppliers add a separate layer of risk, contamination, wrong concentration, unknown impurities, that none of that trial data accounts for.
References
- SS-31 binds with high affinity to cardiolipin on the inner mitochondrial membrane and helps protect cristae architecture in stressed mitochondria (mechanism study). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Birk AV, et al. J Am Soc Nephrol, 2013. https://pubmed.ncbi.nlm.nih.gov/23813215/
- Pivotal phase 3 trial (MMPOWER-3): 218 adults with primary mitochondrial myopathy randomized to 40 mg/day subcutaneous elamipretide or placebo for 24 weeks; no significant difference from placebo on the six-minute walk test or total fatigue, and the trial did not meet its primary or secondary endpoints. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Karaa A, et al. Neurology, 2023. https://pubmed.ncbi.nlm.nih.gov/37268435/ (full text:)
- Elamipretide described as the first cardiolipin-directed mitochondrial therapeutic granted FDA accelerated approval (September 2025) for Barth syndrome, with a confirmatory trial required. Zhao C, Zhuang X, Gao J. Drug Discov Ther, 2026.
- FDA approval record for elamipretide (Forzinity), NDA 215244: accelerated approval to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. U.S. Food and Drug Administration, Drugs@FDA.
- FDA official lists of bulk drug substances for use in compounding under section 503A, including substances flagged for significant safety questions. U.S. Food and Drug Administration.
